Carb-X to Expand Funding of Specific Diagnostics to Support the Development of a Rapid Antibiotic Susceptibility Test to Treat Life-Threatening Blood Infections
CARB-X is featured in Markets Insider.
CARB-X Partnership Pushes Development of New Antibiotics
Kevin Outterson is interviewed in KSL.com.
Inside CARB-X, the Boston Fund on the Front Lines Fighting Antibiotic Resistance
Kevin Outterson is featured in BostonInno.
Our Antibiotics Are Becoming Useless
Kevin Outterson quoted in Vox.
CARB-X Launches New Funding Rounds To Support the Development of Antibiotics, Vaccines, Diagnostics and Other Life-Saving Products That Target Drug-Resistant Bacteria
(BOSTON, MA) – CARB-X announced today its 2019 rounds of funding to support the development of antibiotics, vaccines, biotherapeutics, diagnostics and other life-saving products to address the rising threat of drug-resistant bacteria. There are four funding rounds representing CARB-X’s most ambitious call for proposals from product developers seeking financial, scientific and business support to accelerate […]
Specific Diagnostics Achieves CARB-X Milestone and Advances Its Reveal Rapid Antibiotic Susceptibility Test For Life-Threatening Drug-Resistant Infections
BU Law featured in “Specific Diagnostics Achieves CARB-X Milestone and Advances Its Reveal Rapid Antibiotic Susceptibility Test For Life-Threatening Drug-Resistant Infections,” Benzinga.
ContraFect Announces $6.94 Million in Funding from CARB-X to Support Development of Amurin Platform Against All Gram-negative ESKAPE Pathogens
CARB-X featured in Nasdaq.
Kean University Joins Global Network to Combat Antibiotic-Resistant Superbugs
BU Law featured in NJBIZ.
CARB-X to Fund Antibiotic Development Initiative
Kevin Outterson featured in Homeland Preparedness News.
Forge Achieves CARB-X Milestone To Advance Its LpxC Antibiotic To Treat Infections Caused By The World’s Deadliest ‘Superbugs’
BU Law featured in “Forge Achieves CARB-X Milestone To Advance Its LpxC Antibiotic To Treat Infections Caused By The World’s Deadliest ‘Superbugs'” PR Newswire.